Fig 3. Comparison of survival, clinical GVHD score, and tumor burden among GVHD, GVL with/without alemtuzumab treatment (0.25, 0.5, and 1.0 mg/kg), and leukemia mouse models.

The mice were allocated to one of the following six groups: GVHD, GVL, leukemia, and alemtuzumab treatment at doses of 0.25, 0.5, and 1.0 mg/kg (n = 3 each). The mice were observed every day following transplantation for survival estimates and every other day to calculate their clinical GVHD scores (A). Bioluminescence imaging with photons (line graphs in the middle row) for each group and the status of the mice were observed for 50 days following transplantation (B).